21 CFR Part 211.192

21 CFR § 211.192 requires production and control records, including packaging and labeling records, to be reviewed and approved by the quality control unit before a batch is released or distributed.

The regulation also requires thorough investigation of any unexplained discrepancy or failure of a batch or component to meet specifications. The investigation must extend to other batches of the same drug product and to other drug products that may be associated with the discrepancy or failure. A written investigation record must include conclusions and follow-up.

In CMC practice, § 211.192 is central to batch disposition, deviation management, OOS/OOT investigations, quality-unit release decisions, and cross-batch impact assessment. A batch can meet numerical specifications and still be unsuitable for release if production records, deviations, analytical data, or investigations show unresolved quality concerns.

21 CFR Part 211 applies to current good manufacturing practice for finished pharmaceuticals. For phase 1 investigational drugs, FDA guidance explains that most phase 1 investigational drugs, including biological drugs, are exempt from complying with 21 CFR Part 211 under 21 CFR 210.2(c). However, this exemption no longer applies to a phase 1 drug once that same investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, or once that drug has been lawfully marketed. In those situations, the drug for use in the phase 1 study must comply with Part 211.

This exemption analysis is drug-specific, not a general sponsor-pipeline rule. A sponsor’s unrelated Phase 2 or Phase 3 program does not automatically eliminate the Part 211 exemption for a different Phase 1 investigational drug. Even when the exemption applies, FDA still expects appropriate CGMP controls to protect subjects and support product quality during clinical development.

Production Record Review as a Release Control

Under § 211.192, production and control record review is a release-critical quality-unit function. The review should confirm that the batch was manufactured, packaged, labeled, tested, and documented according to approved procedures before release or distribution.

For CMC teams, this means batch disposition should not rely only on final test results. The quality unit should also evaluate deviations, yield discrepancies, atypical events, incomplete documentation, equipment or material issues, laboratory anomalies, and any investigation that could affect batch quality.

Companion CFR Sections

Section 211.192 does not operate alone. It depends on several related CGMP provisions:

- 21 CFR § 211.160: establishes general laboratory-control requirements, including scientifically sound specifications, standards, sampling plans, and test procedures.
- 21 CFR § 211.188: requires batch production and control records for each drug product batch, including in-process and laboratory control results, yields, equipment/line identity, labeling controls, sampling, and any investigation made under § 211.192.
- 21 CFR § 211.194: requires complete laboratory records, including complete data from tests needed to assure compliance with established specifications and standards.
- 21 CFR § 211.180(e): requires annual evaluation of product quality standards and specifically includes review of investigations conducted under § 211.192.

In practice, § 211.160 and § 211.194 support the laboratory-control and data-review side of the investigation, § 211.188 supports the batch-record and manufacturing-history review, and § 211.180(e) connects individual investigations to annual product review and long-term quality trending.

Investigation Triggers

An investigation is required when there is an unexplained discrepancy or when a batch or component fails to meet specifications. In practice, investigation triggers may include:

- OOS results
- OOT or atypical trends
- unexplained yield excursions
- deviations from approved procedures
- unexpected process or analytical events
- undocumented or poorly documented events
- data-integrity concerns
- discrepancies discovered during batch record review
- in-process, environmental, physical, or component specification failures

OOS results and deviation-related triggers are especially important because they commonly affect batch-disposition decisions and are frequently scrutinized during inspections.

OOS Investigation Structure

FDA’s OOS guidance describes a phased investigation framework. Phase I is the laboratory investigation, focused on the accuracy of laboratory data and whether a clearly assignable laboratory error occurred. If no clearly causative laboratory error is identified, the investigation should move to Phase II, a full-scale investigation that may include review of production, sampling, manufacturing records, additional laboratory testing, and cross-functional input.

An OOS result should not be invalidated simply because later testing passes. Retesting or resampling should follow a predefined, scientifically justified procedure approved by the quality unit. Repeated testing until a passing result is obtained is not a scientifically valid substitute for an investigation.

Extension Beyond the Affected Batch

Section 211.192 specifically requires investigations to extend beyond the affected batch when appropriate. The investigation should evaluate whether other batches of the same drug product, or other products sharing materials, equipment, processes, facilities, personnel, or analytical methods, may be affected.

For CMC practice, this is the regulatory basis for cross-batch impact assessment and evaluation of other potentially affected batches or products. Limiting an investigation to a single batch without a documented scientific rationale can create inspection risk.

Biologics and Gene Therapy Considerations

For licensed biological products, § 211.192 should be understood together with applicable biologics requirements under 21 CFR Parts 600–610. For example, 21 CFR § 610.1 requires completion of applicable lot-release testing before release of a licensed product, and § 610.10 requires potency tests designed for each product to indicate potency in an adequate manner.

For biologics, cell therapies, and gene therapies, investigation conclusions often need to consider product-specific potency, identity, purity, safety, process consistency, analytical method limitations, and limited batch history. A deviation or OOS result may therefore require more than a simple pass/fail conclusion; it may require a scientific assessment of whether the event affects product quality, patient risk, process control, or comparability.

Contract Manufacturing and CDMO Oversight

Many biotech and clinical-stage companies rely on CDMOs or contract testing laboratories. Outsourcing manufacturing or testing does not eliminate the sponsor’s quality responsibility.

A quality agreement should define how batch records, deviations, OOS/OOT results, change controls, investigations, CAPA, and release documentation are communicated, reviewed, and approved. The contract facility may accept or reject the results of its own operations, but final product disposition authority remains with the product owner.

For § 211.192, this means the sponsor or product owner should have a defined process to review CDMO batch records, deviation reports, laboratory investigations, root-cause rationale, cross-batch impact assessments, and CAPA before disposition.

Written Investigation Record

The investigation record should document the issue, data reviewed, investigation approach, root-cause rationale, batch-impact assessment, cross-batch impact assessment, conclusions, CAPA where applicable, and follow-up actions.

An undocumented or verbal investigation is not sufficient. If the investigation supports batch release despite a discrepancy, the rationale should be clear, scientifically justified, and approved by the quality unit.

Timeliness and Open Investigations

Section 211.192 does not prescribe a fixed number of days for completing investigations. However, investigation timeliness is an important inspection consideration. Prolonged open investigations, repeated extensions without justification, or batch release before adequate investigation closure can create inspection risk.

Procedures should define expected timelines, escalation criteria, interim controls, and requirements for quality-unit approval when investigations remain open near a batch-disposition decision.

Root Cause, Human Error, and CAPA

Human error may be identified as a contributing factor, but it should not be used as a superficial endpoint. A scientifically useful investigation should ask why the error was possible and what system controls failed to prevent or detect it.

Relevant contributors may include procedure clarity, training effectiveness, process design, equipment usability, workload, environmental conditions, documentation design, and supervisory review.

CAPA should be proportionate to risk and linked to the root cause or most probable cause. Weak CAPA examples include retraining without evidence that training was the true control gap, corrective actions with no owner or due date, and CAPA closure without effectiveness verification.

Annual Product Review and PQS Linkage

Investigations under § 211.192 should feed into annual product review under § 211.180(e). APR trending can identify repeated deviations, recurring OOS/OOT patterns, process drift, weak CAPA, or product-specific vulnerabilities that may require changes to specifications, manufacturing procedures, control strategy, or analytical methods.

ICH Q10 provides a broader pharmaceutical quality system framework for this lifecycle view. Its concepts of knowledge management, quality risk management, CAPA, management review, and continual improvement support the practical implementation of § 211.192 investigation and batch-disposition expectations.

Practical CMC Meaning

Production and control records must be reviewed before release.
Batch release should wait until batch records, packaging/labeling records, deviations, and relevant QC data are reviewed by the quality unit.

Unexplained discrepancies must be investigated.
Atypical yield, unexplained events, deviations, OOS/OOT results, or unresolved data anomalies should trigger documented evaluation.

Specification failures must be investigated.
A passing result, including a laboratory retest or subsequent in-process measurement, cannot be used to invalidate an initial out-of-specification finding without a documented, scientifically sound investigation.

Investigations must extend to related batches/products.
The investigation should assess whether shared materials, equipment, operators, methods, process steps, or time periods could affect other batches or products.

Written conclusions and follow-up are required.
The record should include the issue, data reviewed, root-cause rationale, batch impact, CAPA if applicable, and disposition decision.

CAPA should address the actual control gap.
CAPA should be risk-based, assigned, time-bound, and verified for effectiveness when appropriate.

Investigation data should be trended.
Recurring investigation themes should feed APR, management review, and PQS improvement activities.

Common FDA 483 Themes

Common inspection observations related to § 211.192 include inadequate investigation of discrepancies, failure to identify or justify root cause, failure to extend investigations to potentially affected batches, weak CAPA rationale, incomplete written records, prolonged open investigations, and release of batches despite unresolved discrepancies.

For biologics, gene therapies, and other complex products, § 211.192 is especially important because manufacturing variability, analytical complexity, limited batch history, and product-specific potency or safety concerns can make documented scientific rationale central to batch disposition.